U.S. Markets open in 7 hrs 39 mins
  • S&P Futures

    4,130.00
    -17.75 (-0.43%)
     
  • Dow Futures

    33,862.00
    -100.00 (-0.29%)
     
  • Nasdaq Futures

    12,553.75
    -70.25 (-0.56%)
     
  • Russell 2000 Futures

    1,983.10
    -10.40 (-0.52%)
     
  • Crude Oil

    73.50
    +0.11 (+0.15%)
     
  • Gold

    1,888.70
    +12.10 (+0.64%)
     
  • Silver

    22.49
    +0.08 (+0.36%)
     
  • EUR/USD

    1.0794
    -0.0002 (-0.0216%)
     
  • 10-Yr Bond

    3.5320
    0.0000 (0.00%)
     
  • Vix

    18.33
    -0.40 (-2.14%)
     
  • GBP/USD

    1.2065
    +0.0009 (+0.0748%)
     
  • USD/JPY

    131.8330
    +0.6830 (+0.5208%)
     
  • BTC-USD

    22,803.12
    -607.57 (-2.60%)
     
  • CMC Crypto 200

    523.80
    -13.06 (-2.43%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,693.65
    +184.19 (+0.67%)
     

Instil Bio Share Sink After Enrollment Pause In Cancer Therapy Trials

  • Instil Bio Inc (NASDAQ: TIL) has voluntarily paused enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 and has notified regulatory authorities in the U.S., Canada, and the U.K.

  • No regulatory agencies have notified the company of a clinical hold in its clinical trials.

  • The voluntary pause was instituted following a recent decreased rate in the successful manufacturing of ITIL-168, resulting in the inability to dose some patients whose individual product of ITIL-168 was not successfully manufactured.

  • A pre-specified safety analysis in the DELTA-1 trial was conducted on patients who received ITIL-168 and did not identify any unexpected safety issues.

  • The company has commenced an end-to-end analysis of its manufacturing processes.

  • Although no manufacturing failures have been observed in the ongoing Phase 1 trial of ITIL-306, the company has also voluntarily paused enrollment in this trial as part of its overall manufacturing analysis.

  • The company intends to provide an update on the manufacturing analysis by early Q1 2023. The company confirms its previously disclosed cash runway into 2025.

  • In May, the FDA signed off ITIL-306 Investigational New Drug (IND), an autologous TIL cell therapy for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC).

  • Price Action: TIL shares are down 26.70% at $3.85 on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.